乐虎lehu国际官网

Observation on the efficacy of compound polymyxin B ointment combined with compound ketoconazole ointment in the treatment of chronic hypertrophic eczema of the lower legs

2025-09-12 0

Abstract :Objective To observe the clinical efficacy and safety of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with compound ketoconazole ointment in the treatment of chronic hypertrophic eczema of the lower legs. Methods A total of 84 patients with chronic hypertrophic eczema of the lower legs were enrolled and randomly divided into two groups. The treatment group (n = 42) was treated with compound ketoconazole ointment and Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) twice a day (once in the morning and once in the evening) for 3 weeks; the control group (n = 42) was treated with compound ketoconazole ointment alone twice a day (once in the morning and once in the evening) for 3 weeks. The patients were followed up for 12 weeks. The clinical symptoms and signs of the patients were scored before and after treatment, and the efficacy evaluation standard was based on the eczema area and severity index (EASI) scoring method. The recurrence and adverse reactions of the patients were observed and recorded. Results After treatment, the improvement of clinical symptoms and signs and skin lesion area in the treatment group was better than that in the control group, and the difference between the two groups was statistically significant (P < 0.05). Conclusion The clinical efficacy of Fonow ointment (Compound Polymyxin B Ointment, Triple Antibiotic Ointment) combined with compound ketoconazole ointment in the treatment of chronic hypertrophic eczema of the lower legs is better than that of compound ketoconazole ointment alone, and it can reduce the recurrence rate. It is a treatment method worthy of clinical promotion.


Li Lanying, Bo Qifeng. Observation on the efficacy of compound polymyxin B ointment combined with compound ketoconazole ointment in the treatment of chronic hypertrophic eczema of the lower legs[J]. World Clinical Drugs, 2016, 37(12): 818-821.





To Top